Events & Presentations

Add Files Arbutus Biopharma Corporate Overview 2.8 MB	Add Files Arbutus Biopharma Corporate Overview 2.8 MB

Upcoming Events

Nov 04,2021 8:45 AM EDT

Archived Events

Summary Toggle Oct 13,2021 1:00 PM EDT	H.C. Wainwright Hepatitis B Virus (HBV) Virtual Conference Listen to webcast
Summary Toggle Oct 11 - 15,2021	The Science of HBV Cure Meeting 2021 (Virtual) Supporting Materials Clinical Overview of AB-729, a potent siRNA in development for the treatment of chronic hepatitis B infection 2.9 MB
Summary Toggle Oct 05,2021 4:30 PM EDT	Chardan’s 5th Annual Genetic Medicines Conference – Virtual Listen to webcast
Summary Toggle Sep 30,2021 8:40 AM EDT	Cantor Global Healthcare Conference - Virtual Listen to webcast
Summary Toggle Sep 26 - 30,2021	2021 International HBV Meeting Supporting Materials Kinetics of HBV DNA replication, cccDNA formation and HBsAg production in a “pgRNA launch” HBV replication system and its susceptibility to antiviral agents 5 MB
Summary Toggle Sep 13,2021 7:00 AM EDT	H.C. Wainwright 23rd Annual Global Investment Conference - Virtual Listen to webcast
Summary Toggle Aug 10,2021 4:05 PM EDT	Wedbush PacGrow Healthcare Virtual Conference Listen to webcast
Summary Toggle Aug 05,2021 8:45 AM EDT	Arbutus Biopharma Corporation 2021 Second Quarter Financial Results and Corporate Update Listen to webcast
Summary Toggle Jun 28,2021 8:00 AM EDT	Clinical Update Based on Data Presented at the EASL International Liver Congress™ 2021 Listen to webcast Supporting Materials Presentation 1.5 MB
Summary Toggle Jun 23 - 26,2021	EASL International Liver Congress™ 2021 Supporting Materials Presentation: Repeat dosing of the GalNAc-siRNA AB-729 in subjects with chronic hepatitis B results in robust and sustained HBsAg suppression 1.6 MB Poster: A single dose of the GalNAc-siRNA AB-729 results in prolonged reductions in HBsAg, HBcrAg, HBV DNA and HBV RNA in the absence of nucleos(t)ide analogue therapy in HBeAg- subjects with chronic hepatitis B infection 424.8 KB Poster: Inhibition of hepatitis B surface antigen by RNA interference therapeutic AB-729 in chronic hepatitis B patients correlates with suppression of all HBsAg isoforms and HBV RNA 498.7 KB Poster: Inhibition of hepatitis B surface antigen in chronic hepatitis B subjects by RNA interference therapeutic AB-729 is accompanied by upregulation of HBV-specific T-cell activation markers 505.1 KB Presentation: Preclinical antiviral profile of AB-836, a potent, highly selective hepatitis B virus capsid inhibitor 1 MB
Summary Toggle Jun 17,2021 11:00 AM EDT	JMP Securities Life Sciences Conference - Virtual Listen to webcast
Summary Toggle Jun 02,2021 9:00 AM EDT	Jefferies Virtual Healthcare Conference Listen to webcast
Summary Toggle May 05,2021 8:45 AM EDT	Arbutus Biopharma Corporation 2021 First Quarter Financial Results and Corporate Update Listen to webcast
Summary Toggle May 05 - 06,2021	Chronic Hepatitis B Drug Development Summit Supporting Materials An RNAi for the Treatment O f Chronic Hepatitis B Infection: Clinical Update 1.7 MB
Summary Toggle Mar 09 - 10,2021	H.C. Wainwright Global Life Sciences Conference
Summary Toggle Mar 04,2021 8:45 AM EST	Arbutus Biopharma Corporation Fourth Quarter and Year End 2020 Financial Results and Corporate Update Listen to webcast Supporting Materials Presentation 1 MB
Summary Toggle Feb 04 - 06,2021	The Asian Pacific Association for the Study of the Liver (APASL) Supporting Materials AB‐729, a GalNAc‐siRNA, results in robust reductions of HBV DNA and HBsAg in subjects with chronic hepatitis B infection APASL 2021 311.3 KB
Summary Toggle Jan 11 - 14,2021	H.C. Wainwright BioConnect 2021 Conference
Summary Toggle Nov 17,2020 12:35 PM EST	Jefferies Virtual London Healthcare Conference Listen to webcast
Summary Toggle Nov 16,2020 8:00 AM EST	AB-729 Clinical Update Click here for webcast Supporting Materials Presentation 802.3 KB
Summary Toggle Nov 15,2020	The Liver Meeting Digital Experience™ \| AASLD Supporting Materials Safety and pharmacodynamics of the GalNAc-siRNA AB-729 in subjects with chronic hepatitis B infection 1.3 MB
Summary Toggle Nov 05,2020 8:45 AM EST	Arbutus Biopharma Corporation 2020 Third Quarter Financial Results and Corporate Update Listen to webcast
Summary Toggle Oct 20,2020 10:00 AM EDT	H.C. Wainwright Hepatitis B Virus (HBV) Mini-Conference
Summary Toggle Oct 05,2020 1:00 PM EDT	Chardan Virtual 4th Annual Genetic Medicines Conference Listen to webcast
Summary Toggle Sep 28 - 30,2020	International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs, Virtual Meeting Supporting Materials Impact of the hepatitis B virus (HBV) capsid inhibitor, AB-506, on the single dose pharmacokinetics (PK) of a combined oral contraceptive (COC) 242 KB Evaluation of relationships between AB-506 related ALT elevations and AB-506 pharmacokinetics (PK), metabolite concentrations and plasma bile acids 1.3 MB
Summary Toggle Aug 29,2020	EASL 2020 Supporting Materials Hepatitis B Virus Core Protein Variants Observed In a First-In-Human Placebo-Controlled Study of a Capsid Inhibitor 709.6 KB
Summary Toggle May 18,2020 4:30 PM EDT	AB-729 Clinical Update Supporting Materials Presentation 593.9 KB
Summary Toggle Mar 26,2020 4:30 PM EDT	AB-729 Clinical Update Supporting Materials Presentation 694.9 KB
Summary Toggle Dec 12,2019	HepDART 2019 Supporting Materials Poster: Key findings leading to the discontinuation of a Capsid Inhibitor (CI), AB-506, in Healthy Subjects (HS) and Chronic Hepatitis B (CHB) Subjects 844.4 KB Presentation: Key findings leading to the discontinuation of a Capsid Inhibitor (CI), AB-506, in Healthy Subjects (HS) and Chronic Hepatitis B (CHB) Subjects 992.3 KB
Summary Toggle Nov 11,2019	AASLD 2019 Supporting Materials A Novel HBV Capsid Inhibitor Compound Series Demonstrates Improved Inhibition of HBV WT, T33N and I105T Core Protein Variants and Shows a Unique Binding Mode to Core Protein 9.8 MB Safety, Tolerability, Pharmacokinetics (PK), and Antiviral Activity of the Capsid Inhibitor (CI) AB-506 in Healthy Subjects (HS) and Chronic Hepatitis B (CHB) Subjects 667.8 KB
Summary Toggle Oct 01 - 05,2019	International HBV Meeting 2019 Supporting Materials Cellular RNA Quality Control Functions Regulate Hepatitis B Virus RNA Steady-State Levels 683.5 KB

Events & Presentations

Presentations

Upcoming Events

Archived Events

Supporting Materials

Supporting Materials

Supporting Materials

Supporting Materials

Supporting Materials

Supporting Materials

Supporting Materials

Supporting Materials

Supporting Materials

Supporting Materials

Supporting Materials

Supporting Materials

Supporting Materials

Supporting Materials

Supporting Materials

Supporting Materials